View Cart  

Daiichi, ArQule End Phase III Drug Combo Trial

A A
Daiichi Sankyo and ArQule are discontinuing a Phase III trial of tivantinib in combination with erlotinib for patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC).

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00